Hospital 30-day readmission rates associated with the Affordable Care Act for heart failure, acute myocardial infarction, and pneumonia are weakly but significantly correlated with reductions in hospital 30-day mortality rates after discharge, according to a new study.
Hospital 30-day readmission rates associated with the Affordable Care Act (ACA) for heart failure (HF), acute myocardial infarction (AMI), and pneumonia are weakly but significantly correlated with reductions in hospital 30-day mortality rates after discharge, according to a new study.
Since the ACA passed there have been reductions in 30-day readmission rates for US Medicare beneficiaries due to the Hospital Readmissions Reduction Program, which required CMS to decrease payments to hospitals with higher readmission rates for certain conditions, including HF, AMI, and pneumonia.
The study, published by JAMA, evaluated the potential correlation between the reductions in hospital readmission rates and greater 30-day mortality rates through identifying all hospitalizations of Medicare fee-for-service beneficiaries at least 65 years old from January 1, 2008, through December 31, 2014, with a discharge diagnosis of HF, AMI, or pneumonia. From this data, the researchers calculated the 30-day risk-adjusted readmission rates and 30-day risk-adjusted mortality rates after discharge for each condition and each month of the study period.
In the study period, there were 2.9 million hospitalizations for HF, 1.2 million for AMI, and 2.5 million for pneumonia. In January 2008, the mean hospital 30-day risk-adjusted readmission rates (RARRs) and 30-day risk-adjusted mortality rates (RAMRs) after discharge were 24.6% and 8.4% after HF hospitalization, 19.3% and 7.6% for AMI, and 18.3% and 8.5% for pneumonia. When considering the changes between 2008 to 2014, RARRs declined by —0.053% for HF, –0.044% for AMI, and –0.033% for pneumonia.
The research also found that the correlation coefficients in hospitals’ paired monthly changes in 30-day RARRs and 30-day RAMRs after discharge were weakly positive.
“Among Medicare FFS beneficiaries hospitalized for HF, AMI, or pneumonia, reductions in hospital 30-day readmission rates were weakly but significantly correlated with reductions in hospital 30-day mortality rates after discharge,” the authors wrote. “While concerns about unintended consequences of incentivizing readmission reduction have been frequently raised, study findings strongly suggest that mortality has not increased.”
In conclusion, the researchers emphasize that the study results do not support the rising post-discharge mortality associated with reducing hospital readmissions.
Racial, Ethnic Disparities May Impact Age Differences at First Heart Failure Hospitalization
September 4th 2025Social determinants of health were associated with a younger age of first hospitalization for heart failure in Black and Hispanic patients when compared with Asian and White patients.
Read More
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
Patients With HFpEF May Benefit From Accelerated Cardiac Pacing
August 28th 2025In an observational extension of the myPACE clinical trial, researchers found that a personalized accelerated pacing in patients with heart failure with preserved ejection fraction (HFpEF) and a preexisting physiological pacer saw a slower trend in adverse cardiac events and overall improved health status.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Finerenone Demonstrates Safety and Efficacy in Heart Failure When Combined With Diuretics
August 13th 2025Clinical trial results establish the safety and efficacy of finerenone to help preserve potassium levels and reduce sodium in patients on diuretics with heart failure and mildly reduced ejection fraction or preserved ejection fraction.
Read More
Genetics, Comorbidities Associated With Cardiomyopathy and Atrial Fibrillation
August 13th 2025The cause of dilated cardiomyopathy (DCM) can be associated with the presence of the TTN gene combined with preexisting comorbidities like atrial fibrillation, which increase the odds of developing DCM.
Read More